Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

  • PERUSE investigators
  • , D. Miles*
  • , E. Ciruelos
  • , A. Schneeweiss
  • , F. Puglisi
  • , T. Peretz-Yablonski
  • , M. Campone
  • , I. Bondarenko
  • , Z. Nowecki
  • , H. Errihani
  • , S. Paluch-Shimon
  • , A. Wardley
  • , J. L. Merot
  • , P. Trask
  • , Y. du Toit
  • , C. Pena-Murillo
  • , V. Revelant
  • , D. Klingbiel
  • , T. Bachelot
  • , K. Bouzid
  • I. Desmoulins, B. Coudert, I. Glogowska, E. Ciruelos Gil, F. Dalenc, F. Ricci, V. Dieras, B. Kaufman, A. Ferreira, M. Mano, H. Kalofonos, C. Andreetta, F. Montemurro, S. Barrett, Q. Zhang, D. Mavroudis, J. Matus, C. Villarreal Garza, C. Beato, G. Ismael, X. Hu, H. Abdel Azeem, R. Gaafar, C. Perrin, P. Kerbrat, J. Ettl, S. Paepke, E. Hitre, I. Lang, M. Trudeau, A. Rody
*Korrespondierende/r Autor/-in für diese Arbeit
  • East and North Hertfordshire NHS Trust
  • University Hospital HM Hospitales
  • Ruprecht-Karls-Universität Heidelberg
  • University of Udine
  • Hebrew University of Jerusalem
  • Institut de Cancérologie de l'Ouest
  • City Clinical Hospital No. 4
  • Mohammed V Rabat University
  • Chaim Sheba Medical Center Israel
  • National Institute for Health and Care Research
  • QuintilesIMS
  • Genentech Incorporated
  • Pharma Research and Early Development (pRED)
  • Centre Leon Berard

Fingerprint

Untersuchen Sie die Forschungsthemen von „Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication“. Zusammen bilden sie einen einzigartigen Fingerprint.
sortieren

Immunology and Microbiology